Evidence map›Paper›PMID 31295521›Full record

ReviewAdvanced drug delivery reviews2019

Subchronic and chronic toxicity evaluation of inorganic nanoparticles for delivery applications.

Raziye Mohammadpour, Marina A Dobrovolskaia, Darwin L Cheney, Khaled F Greish, Hamidreza Ghandehari

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Advanced drug delivery reviews, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 98 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
98citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

98 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review

38 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Raziye MohammadpourUtah Center for Nanomedicine, Nano Institute of Utah, University of Utah, Salt Lake City, Utah, USA.
Marina A DobrovolskaiaNanotechnology Characterization Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, Maryland, USA.
Darwin L CheneyUtah Center for Nanomedicine, Nano Institute of Utah, University of Utah, Salt Lake City, Utah, USA.
Khaled F GreishDepartment of Molecular Medicine, College of Medicine and Medical Sciences, Arabian Gulf University, Manama 329, Bahrain; Nanomedicine Research Unit, Princess Al-Jawhara Centre for Molecular Medicine and Inherited Disorders, Arabian Gulf University, Manama 329, Bahrain.
Hamidreza GhandehariUtah Center for Nanomedicine, Nano Institute of Utah, University of Utah, Salt Lake City, Utah, USA; Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lake City, Utah, USA; Department of Bioengineering, University of Utah, Salt Lake City, Utah, USA. Electronic address: hamid.ghandehari@utah.edu.

Funding

BIOLOGICAL FATE AND BIOCOMPATIBILITY OF SILICA-BASED NANOCONSTRUCTSR01ES024681 · NIEHS · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Hamid Ghandehari · 2014 to 2026
$4.1M
CCR NIH HHS HHSN261200800001CNCI NIH HHS HHSN261200800001ENIEHS NIH HHS R01 ES024681
6 · The paper itself

Abstract

Inorganic nanoparticles provide the opportunity to localize bioactive agents to the target sites and protect them from degradation. In many cases, acute toxicities of inorganic nanoparticles used for delivery applications have been investigated. However, little information is available regarding the long-term toxicity of such materials. This review focuses on the importance of subchronic and chronic toxicity assessment of inorganic nanoparticles investigated for delivery applications. We have attempted to provide a comprehensive review of the available literature for chronic toxicity assessment of inorganic nanoparticles. Where possible correlations are made between particle composition, physiochemical properties, duration, frequency and route of administration, as well as the sex of animals, with tissue and blood toxicity, immunotoxicity and genotoxicity. A critical gap analysis is provided and important factors that need to be considered for long-term toxicology of inorganic nanoparticles are discussed.

Indexed as

AnimalsDrug Delivery SystemsHumansNanoparticlesToxicity Tests, ChronicToxicity Tests, SubchronicDrug deliveryGenotoxicityImmunotoxicityLong-term exposureNanoparticlesNanotoxicologyPhysiochemical propertiesRoute of administrationTissue toxicity

Identifiers

PMID31295521
PMCPMC6745262

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.